References: STAT/Undark Investigation: BPC-157 Science and Safety (Feb 2026) NPR: Influencers Promoting Peptides (Feb 2026) FDA: Bulk Drug Substances List (Category 2) USADA: BPC-157 Prohibited Substances WADA: Prohibited List (S0, S2 categories) DOJ: Tailor Made Compounding prosecution Systematic Review: BPC-157 in Orthopaedic Sports Medicine (2024) Dr
In research, 5-Amino-1MQ is being studied in combination with complementary compounds: caloric restriction (demonstrated synergistic effect on the microbiome), NMN/NR (NAD+ precursors), and physical exercise (sustained performance enhancement)
These injections combine vitamin B12 with lipotropic compounds that help support the bodys ability to metabolize fats and convert food into usable energy
Figure 2: Categorical weight loss of either 5%, 10%, or 15% in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
Daily Regimens: The 1000 mcg Approach A daily 1000 mcg Vitamin B12 dose is often suggested for neuropathy